The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas

Table 1

Evidence of aberrant activation of mTORC1, PI3K/Akt, and Raf/MEK/ERK pathways in B-cell lymphomas.

Lymphoma Type	mTORC1 activation	PI3K/Akt activation	MEK/ERK dysregulation	Ref/s
Hodgkin Lymphoma (HL)	Cell lines, tissue samples	Cell lines, tissue samples		[22]
	Tissue samples			[23, 24]
	Tissue samples	Tissue samples	Tissue samples	[25]
			Cell lines, tissue samples	[26]
Mantle Cell Lymphoma (MCL)	Cell lines, tissue samples	Cell lines, tissue samples		[27, 28]
	Cell lines	Cell lines, tissue samples		[28]
		Cell lines, tissue samples		[29]
	Tissue samples			[30]
	Cell lines, Lymphoma cells from a MCL patient	Cell lines, Lymphoma cells from a MCL patient	Cell lines, Lymphoma cells from a MCL patient	[31]
Diffuse Large B-Cell Lymphoma (DLBCL)	Tissue samples	Tissue samples		[32]
	Cell lines, tissue samples	Cell lines		[33]
		Tissue samples		[34, 35]
		Cell lines, tissue samples		[36, 37]
		Cell lines	Cell lines	[38, 39]
Follicular Lymphoma (FL)	Cell lines, tissue samples			[40]
	Cell lines		Cell lines	[41]
	Cell lines	Cell lines		[42]
		Cell lines		[43, 44]
		Cell lines	Cell lines	[45]
Burkitt Lymphoma	Cell lines			[24]
		Cell lines	Cell lines	[32, 46]
Primary Effusion Lymphoma (PEL)	Cell lines, animal model (mice)	Cell lines, animal model (mice)		[47, 48]
	Cell lines		Cell lines	[24]